Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to May 2014

European Biogerontology Conference In Beer-Sheva, Israel

May 2014

By Ben Best

Cytomegalovirus Is Not Harmless

Pawelec
Pawelec

Graham Pawelec, PhD (Professor, University of Tubingen, Tubingen, Germany) specializes in aging of the immune system due to cytomegalovirus (CMV). CMV can be a life-threatening virus even for those with a healthy immune system.47 Like herpes simplex virus, CMV is usually inactive in infected persons, but is never eliminated by the immune system. Unlike herpes simplex, however, a substantial portion of the immune system is involved in controlling CMV, which drains the resources of the immune system.48,49 Dr. Pawelec noted that death rates in people as a result of cancer and cardiovascular disease cease accelerating by age 75-80, but death rates from infectious diseases continue to accelerate with age indefinitely.50 Persons with the highest levels of CMV antibodies have a much higher risk of death from all causes than persons with few or no antibodies.51,52 CMV is pro-inflammatory, which helps to explain its contribution to immunosenescence and potential relationship with other pathologies.53,54 CMV prevalence increases with age, leveling off at about 85-90% of the population being infected by age 75-80.55 Dr. Pawelec’s team has found that a lower responsiveness to vaccination is associated with CMV infection.56 His team has also found that families having longevity genes have lower levels of CMV-associated alterations in immune function.57 Efforts to develop a vaccine against CMV have not yet been successful.58,59 CMV is transmitted through body fluids such as blood, urine, saliva, vaginal secretions, and semen. Infants are often newly infected, and therefore infectious. Infant caregivers should wash themselves thoroughly with soap and water after changing diapers, feeding, or handling toys. The drug valganciclovir can eradicate active CMV infection.60

Life Extension Contributions To Modern Medicine

Life Extension Contributions To Modern Medicine  

Ilia Stambler, PhD (Researcher, Bar-Ilan University, Tel Aviv, Israel) is a historian of life-extension science.61 The theme of his presentation was that many modern medical therapies had their origin in the efforts of early scientists to find methods of rejuvenation or life extension. Modern hormone replacement therapy originated from 19th century efforts to rejuvenate men using testicular extracts from animals. Similarly, some of the first transplantation operations were attempts at rejuvenation by transplantation of sex glands. Nobel Prize winning researcher Alexis Carrel fostered the idea that cells are immortal in cell culture. Although his techniques proved to be flawed, Carrel was an important contributor to the practice of culturing cells in a growth medium. The first academic institution devoted to blood transfusion was founded in 1925 by a Russian physician who was seeking rejuvenation. Dr. Stambler credits Alexander Bogomolets, a Soviet-era President of the Academy of Sciences of Ukraine, with the use of adjuvants (added components) to potentiate the immune response of the body. Dr. Bogomolets was an ardent life extension proponent. In 1938 Bogomolets organized the first publicized gerontological conference, and he also published his book The Prolongation of Life.

Conference Coverage In The Israeli Media

Dr. Stambler is himself an enthusiastic life extensionist. He was on the organizing committee of this conference. His promotion of the conference in Israeli television and newspapers emphasized the possibilities of life extension. He estimates that these media exposures reached nearly a fifth of the population of Israel.

If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.

References

  1. Seluanov A, Chen Z, Hine C, et al. Telomerase activity coevolves with body mass not lifespan. Aging Cell. 2007 Feb;6(1):45-52.
  2. Seluanov A, Hine C, Azpurua J, et al. Hypersensitivity to contact inhibition provides a clue to cancer resistance of naked mole-rat. Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19352-7.
  3. Tian X, Azpurua J, Hine C, et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature. 2013 Jul 18;499(7458):346-9.
  4. Azpurua J, Ke Z, Chen IX, et al. Naked mole-rat has increased translational fidelity compared with the mouse, as well as a unique 28S ribosomal RNA cleavage. Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17350-5.
  5. Breakthrough of the year 2013. Notable developments. Science. 2013 Dec 20;342(6165):1435-41.
  6. Fontana L, Partridge L, Longo VD. Extending healthy life span--from yeast to humans. Science. 2010 Apr 16;328(5976):321-6.
  7. De Grey AD. Calorie restriction, post-reproductive life span, and programmed aging: a plea for rigor. Ann N Y Acad Sci. 2007 Nov;1119:296-305.
  8. Colman RJ, Anderson RM, Johnson SC, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009 Jul 10;325(5937):201-4.
  9. Mattison JA, Roth GS, Beasley TM, et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature. 2012 Sep 13;489(7415):318-21.
  10. Duffy PH, Seng JE, Lewis SM, et al. The effects of different levels of dietary restriction on aging and survival in the Sprague-Dawley rat: implications for chronic studies. Aging (Milano). 2001 Aug;13(4):263-72.
  11. Raatz SK, Silverstein JT, Jahns L, Picklo MJ. Issues of fish consumption for cardiovascular disease risk reduction. Nutrients. 2013 Mar 28;5(4):1081-97.
  12. Nicholson T, Khademi H, Moghadasian MH. The role of marine n-3 fatty acids in improving cardiovascular health: a review. Food Funct. 2013 Feb 26;4(3):357-65.
  13. Lane MA, Ingram DK, Roth GS. 2-Deoxy-D-glucose feeding in rats mimics physiologic effects of calorie restriction. J Anti-Aging Med. 1998 Winter;1(4):327-37.
  14. Rajpathak SN, Liu Y, Ben-David O, et al. Lifestyle factors of people with exceptional longevity. J Am Geriatr Soc. 2011 Aug;59(8):1509-12.
  15. Sanders AE, Wang C, Katz M, et al. Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. JAMA. 2010 Jan 13;303(2):150-8.
  16. Schechter CB, Barzilai N, Crandall JP, Atzmon G. Cholesteryl ester transfer protein (CETP) genotype and reduced CETP levels associated with decreased prevalence of hypertension. Mayo Clin Proc. 2010 Jun;85(6):522-6.
  17. Atzmon G, Rincon M, Schechter CB, et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol. 2006 Apr;4(4):e113.
  18. Atzmon G, Schechter C, Greiner W, Davidson D, Rennert G, Barzilai N. Clinical phenotype of families with longevity. J Am Geriatr Soc. 2004 Feb;52(2):274-7.
  19. Atzmon G, Rincon M, Rabizadeh P, Barzilai N. Biological evidence for inheritance of exceptional longevity. Mech Ageing Dev. 2005 Feb;126(2):341-5.
  20. Tabatabaie V, Atzmon G, Rajpathak SN, Freeman R, Barzilai N, Crandall J. Exceptional longevity is associated with decreased reproduction. Aging (Albany NY). 2011 Dec;3(12):1202-5.
  21. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10604-9.
  22. Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell. 2013 Jan 24;49(2):359-67.
  23. Mercer TR, Neph S, Dinger ME, et al. The human mitochondrial transcriptome. Cell. 2011 Aug 19;146(4):645-58.
  24. Yen K, Lee C, Mehta H, Cohen P. The emerging role of the mitochondrial-derived peptide humanin in stress resistance. J Mol Endocrinol. 2013 Jan 11;50(1):R11-9.
  25. Muzumdar RH, Huffman DM, Atzmon G, et al. Humanin: a novel central regulator of peripheral insulin action. PLoS One. 2009 Jul 22;4(7):e6334.
  26. Widmer RJ, Flammer AJ, Herrmann J, et al. Circulating humanin levels are associated with preserved coronary endothelial function. Am J Physiol Heart Circ Physiol. 2013 Feb 1;304(3):H393-7.
  27. Thompson LV. Age-related muscle dysfunction. Exp Gerontol. 2009 Jan-Feb;44(1-2):106-11.
  28. Shefer G, Van de Mark DP, Richardson JB, Yablonka-Reuveni Z. Satellite-cell pool size does matter: defining the myogenic potency of aging skeletal muscle. Dev Biol. 2006 Jun 1;294(1):50-66.
  29. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol. 2007 Jan;211(2):144-56.
  30. Warren LA, Rossi DJ. Stem cells and aging in the hematopoietic system. Mech Ageing Dev. 2009 Jan-Feb;130(1-2):46-53.
  31. Oikawa A, Siragusa M, Quaini F, et al. Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):498-508.
  32. Spinetti G, Cordella D, Fortunato O, et al. Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients:implication of the microRNA-155/FOXO3a signaling pathway. Circ Res. 2013 Feb 1;112(3):510-22.
  33. Mangialardi G, Katare R, Oikawa R, et al. Diabetes causes bone marrow endothelial barrier dysfunction by activation of the RhoA-Rho-associated kinase signaling pathway. Arterioscler Thromb Vasc Biol. 2013 Mar;33(3):555-64.
  34. Krizhanovsky V, Yon M, Dickins RA, et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008 Aug 22;134(4):657-67.
  35. Sagiv A, Biran A, Yon M, Simon J, Lowe SW, Krizhanovsky V. Granule exocytosis mediates immune surveillance of senescent cells. Oncogene. 2013 Apr 11;32(15):1971-7.
  36. Gnecchi M, Danieli P, Cervio E. Mesenchymal stem cell therapy for heart disease. Vascul Pharmacol. 2012 Aug 19;57(1):48-55.
  37. Ong WK, Sugii S. Adipose-derived stem cells: fatty potentials for therapy. Int J Biochem Cell Biol. 2013 Jun;45(6):1083-6.
  38. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One. 2010 Apr 26;5(4):e10088.
  39. Adutler-Lieber S, Ben-Mordechai T, Naftali-Shani N, et al. Human macrophage regulation via interaction with cardiac adipose tissue-derived mesenchymal stromal cells. J Cardiovasc Pharmacol Ther. 2013 Jan;18(1):78-86.
  40. Ben-Mordechai T, Holbova R, Landa-Rouben N, et al. Macrophage subpopulations are essential for infarct repair with and without stem cell therapy. J Am Coll Cardiol. 2013 Nov 12;62(20):1890-901.
  41. Naftali-Shani N, Itzhaki-Alfia A, Landa-Rouben N, et al. The origin of human mesenchymal stromal cells dictates their reparative properties. J Am Heart Assoc. 2013 Sep 30;2(5):e000253.
  42. Keren Z, Averbuch D, Shahaf G, et al. Chronic B cell deficiency from birth prevents age-related alterations in the B lineage. J Immunol. 2011 Sep 1;187(5):2140-7.
  43. Lang PO, Govind S, Mitchell WA, Siegrist CA, Aspinall R. Vaccine effectiveness in older individuals: what has been learned from the influenza-vaccine experience. Ageing Res Rev. 2011 Jul;10(3):389-95.
  44. Melamed D, Scott DW. Aging and neoteny in the B lineage. Blood. 2012 Nov 15;120(20):4143-9.
  45. Mehr R, Melamed D. Reversing B cell aging. Aging (Albany NY). 2011 Apr;3(4):438-43.
  46. Keren Z, Naor S, Nussbaum S, et al. B-cell depletion reactivates B lymphopoiesis in the BM and rejuvenates the B lineage in aging. Blood. 2011 Mar 17;117(11):3104-12.
  47. Heininger A, Haeberle H, Fischer I, et al. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis. Crit Care. 2011;15(2):R77.
  48. Hadrup SR, Strindhall J, Køllgaard T, et al. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol. 2006 Feb 15;176(4):2645-53.
  49. Derhovanessian E, Maier AB, Hähnel K, et al. Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans. J Gen Virol. 2011 Dec;92(Pt 12):2746-56.
  50. Pawelec G, Koch S, Franceschi C, Wikby A. Human immunosenescence: does it have an infectious component? Ann N Y Acad Sci. 2006 May;1067:56-65.
  51. Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol. 2010 Aug 15;172(4):363-71.
  52. Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One. 2011 Feb 17;6(2):e16103.
  53. Pawelec G, Larbi A, Derhovanessian E. Senescence of the human immune system. J Comp Pathol. 2010 Jan;142 Suppl 1:S39-44.
  54. Derhovanessian E, Maier AB, Hähnel K, et al. Lower proportion of naïve peripheral CD8+ T cells and an unopposed pro-inflammatory response to human Cytomegalovirus proteins in vitro are associated with longer survival in very elderly people. Age (Dordr). 2013 Aug;35(4):1387-99.
  55. Pawelec G, McElhaney JE, Aiello AE, Derhovanessian E. The impact of CMV infection on survival in older humans. Curr Opin Immunol. 2012 Aug;24(4):507-11.
  56. Derhovanessian E, Theeten H, Hähnel K, Van Damme P, Cools N, Pawelec G. Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine. 2013 Jan 11;31(4):685-90.
  57. Derhovanessian E, Maier AB, Beck R, et al. Hallmark features of immunosenescence are absent in familial longevity. J Immunol. 2010 Oct 15;185(8):4618-24.
  58. Khanna R, Diamond DJ. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med. 2006 Jan;12(1):26-33.
  59. Lilja AE, Mason PW. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB. Vaccine. 2012 Nov 19;30(49):6980-90.
  60. Available at: http://cid.oxfordjournals.org/content/46/1/20.long. Accessed February 19, 2014.
  61. Available at: http://www.longevityhistory.com. Accessed February 17, 2014.